Proteins and Peptides

27 March 2015

Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study of Investigational New Drug Vonapanitase in Chronic Kidney Disease Patients Undergoing Surgical Creation of an Arteriovenous Fistula for Hemodialysis

27 March 2015

BioBlast Pharma Announces Positive Preclinical Proof-of-Concept Results of Its Novel Mitochondrial Protein Replacement Platform in Friedreich’s Ataxia

27 March 2015

Novo Nordisk to Launch Novoeight® in the United States for People With Hemophilia A

27 March 2015

Novo Nordisk A/S : Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US

27 March 2015

Novo Nordisk completes phase 3a trials comparing faster-acting insulin aspart with NovoRapid® in people with type 1 and type 2 diabetes

25 March 2015

BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel Stem Cell Mobilization Treatment

24 March 2015

Saxenda® approved in Europe for the treatment of obesity

24 March 2015

NGM Biopharmaceuticals Announces Positive Phase 2 Clinical Data in Primary Biliary Cirrhosis Patients for NGM282, a First-in-Class Investigational Medicine

24 March 2015

ThromboGenics Announces Positive Topline Results from OASIS Study

24 March 2015

LFB S.A. Receives Go Ahead From Data Monitoring Committee to Expand The Global PERSEPT Phase 3 Program of LR769 in Hemophilia A or B Patients with Inhibitors

19 March 2015

Merz Aesthetics Announces Primary Endpoint Met in Post-Market Clinical Study of Xeomin® (incobotulinumtoxinA) Vs. Botox® (onabotulinumtoxinA) for Glabellar Facial Lines

19 March 2015

Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection

19 March 2015

CollPlant Reports Positive Interim Trial Results for Vergenix®FG Wound Healing Gel

19 March 2015

Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide)

18 March 2015

Allena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the Treatment of Hyperoxaluria

17 March 2015

Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study

16 March 2015

biOasis Releases Results From an Ischemic Stroke Model with Transcend BBB Carrier Peptide (MTfp):MTfp-siRNA Reduces Both the Damage Caused by Infarct and Significantly Improves Neurological Score

16 March 2015

Stealth BioTherapeutics Announces EMBRACE Results: A Phase 2 Clinical Study of Bendavia in Acute Coronary Syndrome

13 March 2015

Baxter BioScience Announces Positive Phase III Results for BAX 817, Investigational Recombinant Treatment for Hemophila A and B Patients with Inhibitors

12 March 2015

Protalex Initiates Enrollment of Phase I/II Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients

10 March 2015

PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen’s investigational enzyme replacement therapies, AGT-182 and AGT-181, for Phase 1 Clinical Trial

9 March 2015

Horizon Pharma plc Announces That Pre-Clinical Data Show Treatment With Interferon Gamma Improved Signs of Disease Severity of Rare Bone Disease

9 March 2015

Novo Nordisk – New data in adults with obesity or who are overweight with comorbidities losing at least 5% body weight with Saxenda® showed improvement in blood glucose, CV risk factors and quality of life outcomes

7 March 2015

Versartis Presents 12-Month Data for VRS-317 at Late-Breaker Session at Endocrine Society’s Annual Meeting

6 March 2015

FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz

6 March 2015

AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV Applying Ropeginterferon ALFA 2B, a Novel, Long-Acting, Mono-Pegylated Interferon for Treatment of Polycythemia Vera

6 March 2015

Chiasma Announces New Data for Investigational Octreotide Capsules

5 March 2015

Capricor Announces Enrollment of Its Phase II Clinical Trial for Cenderitide to Treat Heart Failure

4 March 2015

FDA Accepts Bayer’s Biologics License Application for Investigational Treatment Option in Hemophilia A

2 March 2015

Alizé Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Ustekinumab (Stelara) Biosimilars Pipeline Review

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Ranibizumab (Lucentis) Biosimilars Pipeline Review

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

c-Met-Targeted Antibody Therapy Pipeline Review